“Similar Products at Different Prices: Can Biopharmaceutical Companies Segment Markets?” coauthored by Richard Manning, Christopher Stomberg, Benjamin Scher, Kathleen Chandler, and Andrew Huson, evaluates the economic forces facing drugs that treat macular degeneration and raises important dynamic efficiency considerations regarding incentives for future biologic competition. The article was published in the International Journal of the Economics of Business. Link to the article.
Richard Manning, Christopher Stomberg, Benjamin Scher, Kathleen Chandler, and Andrew Huson
International Journal of the Economics of Business
June 2015